Abstract
Cancer is a hyper-proliferative disease. Whether the proliferative state originates from the cell-of-origin or emerges later remains difficult to resolve. By tracking de novo transformation from normal hematopoietic progenitors expressing an acute myeloid leukemia (AML) oncogene MLL-AF9, we reveal that the cell cycle rate heterogeneity among granulocyte-macrophage progenitors (GMPs) determines their probability of transformation. A fast cell cycle intrinsic to these progenitors provide permissiveness for transformation, with the fastest cycling 3% GMPs acquiring malignancy with near certainty. Molecularly, we propose that MLL-AF9 preserves gene expression of the cellular states in which it is expressed. As such, when expressed in the naturally-existing, rapidly-cycling immature myeloid progenitors, this cell state becomes perpetuated, yielding malignancy. In humans, high CCND1 expression predicts worse prognosis for MLL fusion AMLs. Our work elucidates one of the earliest steps toward malignancy and suggests that modifying the cycling state of the cell-of-origin could be a preventative approach against malignancy.
The Problem: Proliferation as Cause or Consequence?
A central mystery in oncology is why some cells carrying a potent oncogene turn into aggressive tumors while others remain normal. While cancer is defined by hyper-proliferation, it has been difficult to determine if this rapid growth is a consequence of mutation or if the mutation hijacks a cell that was already dividing quickly. Focusing on Acute Myeloid Leukemia (AML) driven by the MLL-AF9 fusion gene, researchers investigated whether the inherent heterogeneity in how fast normal granulocyte-macrophage progenitors (GMPs) cycle determines their likelihood of becoming malignant.
Methods: Single-Cell Tracking and Inducible Models
To resolve this, the researchers developed a "binary" experimental system to track the transition from normal to malignant at the single-cell level. They utilized an inducible iMLL-AF9 mouse model, targeting a single, doxycycline-inducible MLL-AF9 gene into the Hprt locus. This allowed for precise temporal control of oncogene expression across all cells.
Individual GMPs were plated in specialized micro-wells to observe initial division rates before and during oncogene induction. This was complemented by multi-omics (scRNA-seq and ATAC-seq) to map the changing chromatin landscape and cell cycle manipulation using Palbociclib (to slow the cycle) and 5-Fluorouracil (to accelerate it).
Key Insights: The "Snapshot" Mechanism
The study's most profound insight is that MLL-AF9 does not necessarily "reprogram" a cell. Instead, it acts as a molecular "pause button," preserving and perpetuating the gene expression program of the cell at the exact moment of expression. It essentially "locks" the cell in its current developmental and proliferative state.
Within the GMP population, the fastest-cycling 3% of cells transformed into leukemia with near certainty. This suggests that rapid cell division is a requirement for the MLL-AF9 oncogene to function; if activated in a slow-cycling cell, malignancy often fails to take hold. ATAC-seq data supported this "freezing" effect, showing that MLL-AF9 prevents the normal closing of progenitor-associated chromatin regions.
Key Results: Transformation and Survival
The experimental data demonstrated a clear correlation between initial cycling speed and malignancy. GMPs that divided three or more times within the first 24 hours were significantly more likely to form malignant colonies.
As shown in the survival data, induction of the oncogene (+Dox) led to rapid lethality in mouse models, whereas the absence of induction (-Dox) maintained 100% survival. Furthermore, pharmacological intervention with Palbociclib to mildly slow the cell cycle reduced transformed colony formation by approximately 50% and significantly prolonged survival. Conversely, inducing "emergency" blood production with 5FU accelerated leukemia onset, proving that the proliferative state of the cell-of-origin is a primary determinant of transformation efficiency.
Clinical Implications and Future Work
This "fast-cycling" signature has direct human relevance. In patients with MLL-fusion AML, high expression of CCND1 (Cyclin D1) predicts significantly worse survival outcomes. This suggests that the speed of the internal cellular clock at the time of mutation is a major driver of disease severity. Future research into "mitotic bookmarking"—how cells remember their identity during division—may reveal how MLL-AF9 locks in these states, potentially opening new avenues for preventative therapies that "calm" high-risk cell populations before they turn malignant.
Summary updated